Corticosteroids reduce short-term and long-term mortality in adult sepsis patients according to a systematic review.

This systematic review and network meta-analysis assessed the efficacy and safety of corticosteroids in adult patients with sepsis. The study population comprised 7,591 individuals, though the specific settings of the included trials were not reported. The interventions evaluated included hydrocortisone alone and the combination of hydrocortisone plus fludrocortisone. The primary outcomes examined were mortality rates at 30 days or less and at 90 days or more. Secondary outcomes included ICU length of stay, ventilator-free days, vasopressor-free days, and renal replacement therapy-free days. The comparator group details were not reported in the available data.

The analysis demonstrated a reduction in mortality at 30 days or less, with a risk ratio of 0.22 and a 95% confidence interval of 0.072 to 0.62. Mortality reduction was also observed at 90 days or more, with a reported risk ratio of 0.33. A second result for 90-day mortality indicated a risk ratio of 0.79. Absolute numbers for these mortality outcomes were not reported. Statistical significance or confidence intervals for the 90-day mortality results were not provided in the input data.

Regarding secondary outcomes, the review found that ICU length of stay was shortened by a mean difference of -2.6 days. Data regarding ventilator-free days, vasopressor-free days, and renal replacement therapy-free days indicated an increase in these favorable metrics, though specific effect sizes and confidence intervals were not reported for these secondary endpoints.

Safety and tolerability findings were not reported in the input data. Adverse events, serious adverse events, discontinuations, and overall tolerability profiles were not detailed. Consequently, a comprehensive safety assessment cannot be derived from the provided evidence.

The mortality benefit associated with a hydrocortisone dosage of 100 mg/day is described as preliminary. This limitation stems from the reliance on evidence from a single small randomized controlled trial. Furthermore, no consensus exists regarding an optimal dosage for corticosteroid therapy in this context. The review highlights that further research is needed to refine dosage regimens and personalize therapy for individual patients.

Methodological limitations include the lack of reported settings for the included studies and the absence of data on adverse events. The certainty of the evidence regarding mortality benefit is constrained by the small sample size of the pivotal trial for the 100 mg/day dose. These factors suggest that the findings should be interpreted with caution, particularly regarding the generalizability of the results and the definitive nature of the mortality reduction claims.

Clinical implications suggest that while corticosteroids may reduce mortality and ICU stay, practitioners must recognize the preliminary nature of the high-dose hydrocortisone data. Questions remain unanswered regarding the optimal dosage, the necessity of fludrocortisone combination, and the full safety profile of these interventions. The lack of reported adverse events limits the ability to counsel patients on potential risks.

In summary, this review indicates potential mortality benefits for corticosteroids in sepsis but underscores the need for more robust data to confirm these findings and establish standard dosing protocols. The evidence is insufficient to draw definitive conclusions on safety or the superiority of specific regimens over others without further investigation.